Now Reading: Patient Dies After Gene Editing Trial in China
-
01
Patient Dies After Gene Editing Trial in China
A patient with Duchenne muscular dystrophy died after receiving a gene editing therapy from Shanghai-based HuidaGene Therapeutics, the company said on Wednesday. The death occurred in August 2025 and was attributed to…
The Story in Brief
A patient with Duchenne muscular dystrophy died after receiving a gene editing therapy from Shanghai-based HuidaGene Therapeutics, the company said on Wednesday. The death occurred in August 2025 and was attributed to acute respiratory distress syndrome during a severe immune reaction to the treatment.
HuidaGene did not identify the patient or provide further details. Clinical trial records suggest the study enrolled boys aged four to eight. The Times of India reports that the disclosure followed a months-long probe by STAT News. Science had also reported the previously unreported death of a girl in a separate investigator-led trial. Chinese authorities have launched probes into the cases.
The Indian Opinion
The easy narrative is that China’s biotechnology push makes clinical safeguards irrelevant, while the opposite claim would treat one death as proof that gene editing cannot work. Neither follows from the available facts. The missing patient details and unanswered questions about HuidaGene’s next steps point to a transparency problem first. Investigators should publish the trial findings, including how many patients were treated and the confirmed cause of death.
Source: timesofindia.indiatimes.com
This story was synthesised by AI from the source linked above.
